These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23553755)

  • 1. Evaluation of biodegradable paclitaxel-eluting nanofibre-covered metal stents for the treatment of benign cardia stricture in an experimental model.
    Zhu YQ; Cui WG; Cheng YS; Chang J; Chen NW; Yan L
    Br J Surg; 2013 May; 100(6):784-93. PubMed ID: 23553755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodegradable rapamycin-eluting nano-fiber membrane-covered metal stent placement to reduce fibroblast proliferation in experimental stricture in a canine model.
    Zhu YQ; Cui WG; Cheng YS; Chang J; Chen NW; Yan L; Li MH
    Endoscopy; 2013 Jun; 45(6):458-68. PubMed ID: 23580413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporary placement of a paclitaxel or rapamycin-eluting stent is effective to reduce stenting induced inflammatory reaction and scaring in benign cardia stricture models.
    Wang L; Zhu YQ; Cheng YS; Cui WG; Chen NW
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():69-74. PubMed ID: 25910372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A highly flexible paclitaxel-loaded poly(ε-caprolactone) electrospun fibrous-membrane-covered stent for benign cardia stricture.
    Zhu Y; Hu C; Li B; Yang H; Cheng Y; Cui W
    Acta Biomater; 2013 Sep; 9(9):8328-36. PubMed ID: 23770223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.
    Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR
    EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
    Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
    N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE
    EuroIntervention; 2012 May; 8(1):117-9. PubMed ID: 22580255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue hyperplasia: influence of a paclitaxel-eluting covered stent--preliminary study in a canine urethral model.
    Shin JH; Song HY; Choi CG; Yuk SH; Kim JS; Kim YM; Yoon CJ; Kim TH; Suh JY; He X
    Radiology; 2005 Feb; 234(2):438-44. PubMed ID: 15671001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation.
    Jeong YH; Hong MK; Lee CW; Park DW; Kim YH; Kim JJ; Park SW; Park SJ
    Int J Cardiol; 2008 Mar; 125(1):36-40. PubMed ID: 17521753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents.
    Chieffo A; Foglieni C; Nodari RL; Briguori C; Sangiorgi G; Latib A; Montorfano M; Airoldi F; Michev I; Carlino M; Colombo A; Maseri A
    Am J Cardiol; 2009 Dec; 104(12):1660-7. PubMed ID: 19962471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.
    Stone GW; Lansky AJ; Pocock SJ; Gersh BJ; Dangas G; Wong SC; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Möckel M; Ochala A; Kellock A; Parise H; Mehran R;
    N Engl J Med; 2009 May; 360(19):1946-59. PubMed ID: 19420364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and study design of the OISTER trial: optical coherence tomography evaluation of stent struts re-endothelialization in patients with non-ST-elevation acute coronary syndromes--a comparison of the intrEpide tRapidil eluting stent vs. taxus drug-eluting stent implantation.
    Iaccarino D; Politi L; Rossi R; Sgura F; Monopoli D; Modena MG; Sangiorgi GM
    J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):536-43. PubMed ID: 20090547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.
    Markovic S; Paliskyte R; Rottbauer W; Wöhrle J
    Cardiovasc Revasc Med; 2012; 13(6):307-10. PubMed ID: 23164475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions.
    Kim YH; Park SW; Lee CW; Hong MK; Gwon HC; Jang Y; Lee MM; Koo BK; Oh DJ; Seung KB; Tahk SJ; Yoon J; Park SJ
    Catheter Cardiovasc Interv; 2006 Feb; 67(2):181-7. PubMed ID: 16400663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial function rather than endothelial restoration is altered in paclitaxel- as compared to bare metal-, sirolimusand tacrolimus-eluting stents.
    van Beusekom HM; Sorop O; van den Heuvel M; Onuma Y; Duncker DJ; Danser AH; van der Giessen WJ
    EuroIntervention; 2010 May; 6(1):117-25. PubMed ID: 20542807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel-eluting versus bare-metal stents in acute ST elevation myocardial infarction (STEMI).
    Hamirani YS; Jibrin I; Abraham D; Merriman B; Wenz C; Bahr RD
    Crit Pathw Cardiol; 2008 Dec; 7(4):232-8. PubMed ID: 19050419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
    J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
    Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
    N Engl J Med; 2004 Jan; 350(3):221-31. PubMed ID: 14724301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.